A review assesses neurofilament light chain as a biomarker in ALS and other neurological diseases
Original source
Neurofilament Light Chain as a Biomarker in Neurology. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human
Population inferred from the title and abstract by Compass.
Related topics
A narrative review assesses neurofilament light chain (NfL) for diagnosis, prognosis and treatment monitoring across neurological diseases. In amyotrophic lateral sclerosis (ALS), the review reports that higher NfL levels are associated with disease severity and survival. It also highlights factors that can affect NfL measurements and the potential value of combining NfL with other biomarkers.
Why this matters
NfL may help researchers and clinicians assess disease severity and prognosis in ALS. However, differences related to age, kidney function, body mass index and other health conditions make individual results harder to interpret, and the review does not establish a treatment decision or a universally reliable cutoff for patients.
Limitations and context
This is a narrative review, not a new clinical study. It synthesizes existing evidence and identifies future priorities, including age-adjusted reference ranges and validated longitudinal thresholds. The review does not itself establish that NfL improves patient outcomes or is ready for routine treatment monitoring.